RIGL 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

RIGL ▲ +13.61% at T+20d

SHORT call ✗ call lost -13.61% · α vs SPY -10.83% · entry $26.67 → $30.30

Next anchor: T+60d in 6w

Last close $32.85 (close Jun 12) · -23.17% from $26.67 entry (call sign-flipped)

Entry anchored
May 5, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α -0.33%

$26.67

settled 6w ago

T+5d

+10.12%

call -10.12% · α -8.99%

$29.37

settled 5w ago

T+20d

+13.61%

call -13.61% · α -10.83%

$30.30

settled 12d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, missing consensus of $0.74 by 40.5%, despite 10% YoY revenue growth to $58.8M. Net income declined 24% YoY to $8.7M, and the company maintained its full-year revenue guidance of $275-290M. The miss was driven by higher R&D and SG&A costs, overshadowing strong product sales growth.

Key Financial Metrics

Guidance

$275M to $290M

maintained

Actionable Insight

The 40% EPS miss signals deteriorating profitability despite revenue growth. Watch for analyst downgrades and potential cost-cutting measures. The reaffirmed guidance provides a floor, but the collaboration termination adds pipeline uncertainty. Monitor next quarter's margins and any updates on the R289 Phase 1b study.

Key Facts

Q1 2026 total revenues: $58.8M (up 10% YoY from $53.3M)
Net product sales: $54.9M (up 26% YoY)
GAAP diluted EPS: $0.44 vs consensus $0.74 (40.5% miss)
Net income: $8.7M vs $11.4M in Q1 2025 (down 24%)
2026 revenue guidance reaffirmed at $275-290M
Eli Lilly terminated collaboration on ocadusertib (effective June 15, 2026)
Debt restructured: repaid $40M term loan, drew $8M on new $40M revolver
Cash, cash equivalents and short-term investments: $146.7M as of March 31, 2026

Financial Impact

EPS miss of $0.30 vs consensus; net income decline of $2.8M YoY

epsnet incomeoperating expenses

Risk Factors

Eli Lilly collaboration termination may impact future royalty streams
Rising R&D and SG&A expenses pressuring margins
High dependence on TAVALISSE sales (68% of product revenue)
Potential need for additional capital if profitability continues to decline

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

67% bullish (12 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001034842-26-000033
Document: 0001034842-26-000033-index.html	0001034842-26-000033
Document: 0001034842-26-000033.txt	0001034842-26-000033
8-K Data (Synthetic)	0001034842-26-000033

6 reports for RIGL

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for RIGL — sortable, filterable
	Type				Now
Jun 11, 2026 3d ago	Institutional Cluster NEUTRAL ★ 3/10	$31.15 awaiting T+5	awaiting T+5	—	$32.85 (+5.46%)
May 20, 2026 25d ago	8-K NEUTRAL ★ 2/10	$29.19 $30.05	▲ +2.95%	▲ +1.35%	$32.85 (+12.54%)
May 12, 2026 4w ago	8-K BULLISH ★ 7/10	$32.13 $28.30	▼ −11.92%	▼ −10.76%	$32.85 (+2.24%)
May 5, 2026 5w ago	8-K BEARISH ★ 7/10	$26.67 $29.37	▼ −10.12%	▼ −8.99%	$32.85 (−23.17%)
Apr 21, 2026 7w ago	8-K BEARISH ★ 7/10	$30.47 $29.16	▲ +4.30%	▲ +4.35%	$32.85 (−7.81%)
Apr 3, 2026 10w ago	DEFA14A NEUTRAL ★ 2/10	$27.36 $29.97	▲ +9.54%	▲ +5.40%	$32.85 (+20.07%)

US Market Status

Market Closed — Opens in 4h 39m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access